Previous work has shown that encorafenib monotherapy is sufficient to downregulate the RAS/BRAF/MAPK signaling pathway and strongly decreases cancer cell viability in BRAF mutant melanoma tumors (39, 40). The gene discussed is BRAF; the disease is melanoma.